Calcium Supplements in the Treatment of Hypoparathyroidism.

This letter addresses the treatment of hypoparathyroidism, focusing on the role of calcium supplements. It highlights that while calcium carbonate and citrate salts show no difference in managing symptoms or plasma calcium levels, the necessity of calcium supplements for most patients is questionable. The author explains that activated forms of vitamin D, such as alfacalcidol or calcitriol, effectively bypass the impaired conversion of vitamin D in hypoparathyroidism, enabling adequate calcium absorption without additional calcium supplements. Citing studies and surveys, the letter suggests many patients can be managed safely with activated vitamin D alone, and discontinuing calcium supplements may reduce adverse effects and hospital admissions. The letter calls for a reevaluation of current guidelines that consider calcium supplements a mainstay of treatment despite limited supporting evidence.